Delivery Order SPE2DB22D3004-SPE2DB25FQF18
Award Date
4/9/25
Potential Completion Date
4/10/25
Potential Value
$12K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a $15,280.64 firm-fixed-price delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of REXULTI 2 MG TABLET 30S, a pharmaceutical product, with a performance period through March 27, 2025. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, which provides a comprehensive range of...
The U.S. Defense Logistics Agency (DLA) awarded a $6,495.49 firm-fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of 1 mg REXULTI tablets. This order is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999 that AmerisourceBergen holds with DLA Troop Support Medical to provide a comprehensive range of pharmaceutical and medical supplies in support of military healthcare programs. The contract does not have a set-aside designation and is expected to...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide REXULTI 2 mg tablets. The $3,234.78 contract has an ultimate completion date of April 1, 2024. This award is part of a larger indefinite delivery contract (IDC) awarded solely to AmerisourceBergen Drug Corp with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract (SPE2DB24FGF00) to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the provision of pharmaceutical products including REXULTI 1 mg tablets. The $1,819.86 contract has an ultimate completion date of March 21, 2024. AmerisourceBergen Drug Corp is the prime contractor on this delivery order, which is part of a larger indefinite delivery contract (IDC) with a potential value...
This is a $6,945.70 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of REXULTI 2 MG TABLET 30S, a pharmaceutical product, with a period of performance through April 4, 2025. The contract was not set aside for any specific business type. AmerisourceBergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract...
This is a $3,922.63 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract provides for the delivery of REXULTI 0.5 MG TABLET 30S, a pharmaceutical product, to support military healthcare programs. The contract has a period of performance through February 13, 2025 and is not designated as a set-aside. AmerisourceBergen is the prime contractor and holds a...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide the pharmaceutical product REXULTI 0.5 MG TABLET 30S. The order has a completion date of March 8, 2024 and a potential value of $4,592.77. Amerisourcebergen Drug Corp is a prime contractor that holds an indefinite delivery contract (IDC) with DLA, valued up to $999,999,999.00 through December 31, 2025, to deliver a...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the provision of 4,563,969,451 REXULTI 0.5 mg tablets in quantities of 30. The $3,448.07 award has an ultimate completion date of March 15, 2024. This delivery order is part of a larger $999,999,999.00 indefinite delivery contract (IDC) awarded solely to AmerisourceBergen Drug Corp, which serves as the primary vehicle for...
The U.S. Defense Logistics Agency (DLA) has awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the provision of the pharmaceutical product REXULTI 1 MG TABLET 30S. The contract, valued at $1,436.77, has an ultimate completion date of April 15, 2024. Amerisourcebergen Drug Corp, through its Corporate Office division located in Conshohocken, Pennsylvania, is the prime contractor on this award. This delivery order...
The U.S. Defense Logistics Agency (DLA) awarded Amerisourcebergen Drug Corporation, a subsidiary of Amerisourcebergen Corporation, a firm fixed price delivery order contract valued at $6,296.68 for the supply of REXULTI 0.5 MG TABLET 30S. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp by DLA, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary contract...